drugset / Trial / NCT00355082

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

NCT00355082

Phase 3 Completed 226 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.

Timeline

Start
2006-05
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 250 mg
Subject Lamotrigine Small molecule 300 mg

Indications